Dicerna Pharmaceuticals’ (DRNA) “Neutral” Rating Reiterated at Chardan Capital

Dicerna Pharmaceuticals (NASDAQ:DRNA)‘s stock had its “neutral” rating restated by equities researchers at Chardan Capital in a research note issued on Tuesday.

Several other analysts have also recently commented on DRNA. Evercore ISI assumed coverage on Dicerna Pharmaceuticals in a report on Tuesday. They set an “outperform” rating and a $14.00 target price on the stock. BidaskClub cut Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. ValuEngine upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Zacks Investment Research cut Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 7th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $8.25.

Shares of Dicerna Pharmaceuticals (DRNA) opened at $8.83 on Tuesday. The company has a market capitalization of $463.22, a price-to-earnings ratio of -2.57 and a beta of 2.85. Dicerna Pharmaceuticals has a 1-year low of $2.42 and a 1-year high of $10.24.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.22). The business had revenue of $0.47 million for the quarter. Dicerna Pharmaceuticals had a negative return on equity of 293.25% and a negative net margin of 5,895.26%. The business’s revenue was up 192.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.68) EPS. equities analysts forecast that Dicerna Pharmaceuticals will post -2.93 earnings per share for the current fiscal year.

In other news, Director Bain Capital Life Sciences Inv purchased 285,000 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were acquired at an average price of $7.00 per share, for a total transaction of $1,995,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 29.41% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Northern Trust Corp boosted its holdings in Dicerna Pharmaceuticals by 6.1% in the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 2,094 shares during the last quarter. Birchview Capital LP boosted its holdings in Dicerna Pharmaceuticals by 125.0% in the third quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 25,000 shares during the last quarter. Deschutes Portfolio Strategy LLC bought a new position in Dicerna Pharmaceuticals in the third quarter valued at about $575,000. Vanguard Group Inc. boosted its holdings in Dicerna Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after acquiring an additional 14,517 shares during the last quarter. Finally, Palo Alto Investors LLC boosted its holdings in Dicerna Pharmaceuticals by 4.0% in the second quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock valued at $1,588,000 after acquiring an additional 19,394 shares during the last quarter. Institutional investors and hedge funds own 21.93% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/20/dicerna-pharmaceuticals-drna-neutral-rating-reiterated-at-chardan-capital.html.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply